On the other hand, biological agents targeting TNF, IL-23 and IL-17 have shown promising efficacy during the clinical treatment of psoriasis, while IL-6 inhibitors, IL-21 inhibitors and recombinant human IL-10 treatment didn’t attain the results as expected. The gene discussed is IL21; the disease is psoriasis.